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Edited by Laszlo NagyAbstract Fibroblast growth factor 21 (FGF21) is active in mur-
ine adipocytes and has beneﬁcial metabolic eﬀects in animal
models of type 2 diabetes mellitus. We assessed whether
FGF21 inﬂuences lipolysis in human adipocytes and 3T3-L1
cells. FGF21 had no short-time eﬀect (h) while a 3-day incuba-
tion with FGF21 attenuated hormone-stimulated lipolysis.
FGF21 did not inﬂuence the mRNA expression of genes involved
in regulating lipolysis, but signiﬁcantly reduced the expression of
the lipid droplet-associated phosphoprotein perilipin without
aﬀecting diﬀerentiation. Via reduced release of fatty acids into
the circulation, the anti-lipolytic eﬀect could be a mechanism
through which FGF21 promotes insulin sensitivity in man.
 2008 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Fibroblast growth factor 21 (FGF21) is predominantly ex-
pressed in murine liver and thymus [1]. Little was known
regarding the bioactivity of this molecule until it was demon-
strated that FGF21 stimulates non-insulin dependent glucose
uptake in adipocytes [2]. This eﬀect is mediated via increased
expression of glucose transporter-1 (GLUT1). However, no ef-
fect on GLUT 1 expression or glucose uptake can be observed
in non-diﬀerentiated adipose precursor cells or muscle and li-
ver cell lines. In vivo administration of FGF21 in rodent mod-
els of diabetes lowers both plasma glucose and triglyceride
levels and improves insulin sensitivity and glucose clearance.
Transgenic mice over expressing FGF21 from the liver display
resistance to diet-induced obesity and have improved glycemic
control. FGF21 administration in diabetic monkeys results in
a similar beneﬁcial phenotype including improvements in lipo-
protein proﬁles [3]. In diabetic rodents, FGF21 directly aﬀects
the endocrine function of the pancreas by enhancing insulin
production and beta cell survival and reduces the maladaptiveAbbreviations: qRT-PCR, quantitative reverse-transcribed polymerase
chain reaction; PPARc, peroxisome proliferators-activated receptor
gamma; HSL, hormone sensitive lipase; PLIN, perilipin; PKA, protein
kinase A; PDE3B, phosphodiesterase 3B; ANP, atrial natriuretic
peptide; NA, noradrenaline
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doi:10.1016/j.febslet.2008.04.038glucagon release [4]. Recent data have also shown that FGF21
can stimulate lipolysis in murine adipocyte [5]. FGF21 requires
the presence of the transmembrane protein b-klotho for its ef-
fects [6]. So far, there have been no reports regarding the
expression of this gene in human adipocytes.
Insulin sensitivity is inﬂuenced by diﬀerent metabolic pro-
cesses. In obesity and other insulin resistant conditions, a dys-
regulation of adipocyte lipolysis has been shown to be an
important pathogenic process (reviewed in [7]). Via increased
lipolysis in white adipose tissue, circulating non-esteriﬁed fatty
acids (NEFA) are transported to the liver in elevated concen-
trations, which increases the production of very low density
lipoprotein particles followed by hyperlipidemia. In addition,
NEFAs are preferentially oxidized by muscle thereby attenuat-
ing glucose uptake in this tissue. Finally, NEFAs may have di-
rect negative eﬀects on beta cell function and insulin release
(i.e. lipotoxicity).
Lipolysis is regulated by several proteins including perilipin
(PLIN), a phosphoprotein that coats the intracellular lipid
droplet and is phosphorylated by protein kinase A (PKA)
upon lipolytic stimulation. It is believed that this results in
the recruitment of lipases (mainly hormone sensitive lipase,
HSL) to the surface of the lipid droplet for subsequent triglyc-
eride hydrolysis [7]. PLIN phosphorylation increases the
molecular weight of the protein which corresponds to a small
transition of PLIN protein on SDS–PAGE (by approx. 2 kDa)
[8].
Given the rather selective eﬀects of FGF21 on adipocytes we
assessed whether FGF21 could inﬂuence lipolysis in human fat
cells.2. Materials and methods
2.1. FGF21, tissue material, cell isolation and lipolysis
Human and murine FGF21 was obtained as described earlier [2].
Subcutaneous white adipose tissue was obtained from individuals
undergoing surgery for non-malignant disorders. They were otherwise
healthy and free of medication. The studies were approved by the eth-
ical committee at Karolinska Institutet and explained in detail to each
subject and informed consent was obtained. Isolation of mature fat
cells, in vitro diﬀerentiation of primary preadipocytes and subsequent
lipolysis experiments were performed exactly as described [9]. Human
mesenchymal stem cells (hMSCs) were seeded at 10000 cells/well into
96-well plates and cultured for 2 days under supplier (Biowhitaker)
growth recommendations followed by 10 days of culture under diﬀer-
entiation conditions ±FGF21. Medium for adipogenic diﬀerentiation
included combinations of 1 lM dexamethasone, 0.2 mM indometha-
cin, 1.7 lM insulin, 0.5 mM 3-isobutyl-1-methylxanthine (Sigma, St.ation of European Biochemical Societies.
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IN). The cells were then ﬁxed and stained with 2 mM Nile red and
2 mM Syto 16 green (Molecular Probes), and ﬂuorescence was mea-
sured and analyzed with Acumen instrument and software. 3T3-L1
cells were maintained at subconﬂuence and diﬀerentiated into adipo-
cytes as previously described [2]. Cells were diﬀerentiated for 14–21
days, incubated for 16 h in DMEM/0.1% bovine serum albumin
(BSA) and treated with FGF21 for 8 h at the indicated concentrations
in DMEM/0.1% BSA prior to undergoing the assay. Glycerol content
of the culture media was quantitated using an Adipolysis Assay Kit
(Millipore, Billerica, MA) according to the manufacturers instructions
and absorbance was measured at 540 nm using a SpectraMax 190 spec-
trophotometric plate reader (Molecular Devices, Sunnyvale, CA).2.2. RNA analysis and protein expression
Total RNA extraction, primer sequences for quantitative reverse-
transcribed polymerase chain reaction (qRT-PCR) and protein isola-
tion from adipocyte cultures are described previously [9]. The PLIN
antibody was from Progen Biotechnik (Heidelberg, Germany) and b-
actin from Sigma and Western blots were performed as described pre-
viously [10]. Antigen–antibody complexes were detected by chemilumi-
nescence (Supersignal, Pierce, Rockford, USA) and speciﬁc bands
were measured using a Chemidoc XRS system (BioRad, Germany).
Images were analyzed using the Quantity One Software supplied by
the manufacturer (BioRad).2.3. MAPK assay
Total ERK phosphorylation was assessed using an AlphaScreen
SureFire Phospho-ERK1/2 Assay Kit (Perkin–Elmer, Waltham, MA,
USA) according to the manufacturers instructions. An EnVision Mul-
tilabel Microplate Reader Model 2103 with the AlphaScreen HTS Tur-
bo option was used for signal detection (Perkin–Elmer).
2.4. Statistical analysis
Values are means ± standard deviation (S.D.) and compared with
Students paired t-test unless otherwise stated. P < 0.05 was considered
as statistically signiﬁcant.Fig. 1. Lipolysis experiments. (A) Preadipocytes were diﬀerentiated for 12 da
72 h, parallel incubations without FGF21 served as controls as indicated. Aft
106 mol/l noradrenaline (NA) or 105 mol/l Forskolin for 2 h after which
bioluminescence. (B) Cells treated as in (A) but lipolysis was stimulated w
collagenase extraction and incubated in suspension in the presence of 106 n
(INS + NA) or FGF21 (FGF21 + NA). Glycerol release was analyzed. All ex
diﬀerent donors. *P < 0.05 by Students paired t-test for control versus FGF3. Results
3.1. FGF21 attenuates stimulated lipolysis in human adipocytes
in culture
Diﬀerentiated primary human adipocytes were incubated
with diﬀerent concentrations of FGF21 ranging up to
150 nmol/l for diﬀerent time periods. Glycerol release (lipolysis
index) was measured. Incubations for 2–12 h had no eﬀect on
basal or catecholamine-stimulated lipolysis (values not shown)
but a 72 h-incubation with FGF21 signiﬁcantly attenuated
noradrenaline (NA) action (Fig. 1A). This was a post-receptor
eﬀect since lipolysis induced by the adenylate cyclase activator
forskolin was decreased by FGF21. FGF21 also inhibited at-
rial natriuretic peptide (ANP)-stimulated lipolysis in separate
experiments (Fig. 1B) but did not inﬂuence basal glycerol re-
lease (Fig. 1A and B). The maximum FGF21 eﬀect was ob-
served in cells pre-treated with 150 nmol/l (data not shown).
Therefore, this concentration of FGF21 was used in all further
experiments. Acute (2 h) experiments were also performed with
suspensions of freshly isolated fat cells. NA caused a three-fold
induction of lipolysis (Fig. 1C). This eﬀect was signiﬁcantly
attenuated by co-incubation with insulin but there was no ef-
fect on lipolysis with FGF21.
3.2. Human adipocytes express b-klotho, a required protein for
FGF21 signalling
To assess whether human adipocytes express the necessary
components for FGF21 response we performed qRT-PCR in
cell fractions of white adipose tissue. This showed that b-klo-
tho is expressed predominantly in the adipocyte fraction and
less in the stroma-vascular portion (containing undiﬀerentiated
preadipocytes, endothelial cells and immune cells) (Fig. 2A).ys. At this time-point, 150 nmol/l FGF21 was added to the cultures for
er incubation, cells were washed and incubated without (Basal) or with
the media was removed and analyzed for glycerol concentration by
ith 106 mol/l ANP. (C) Freshly isolated fat cells were isolated by
mol/l NA without or with a 2 h preincubation with 106 mol/l insulin
periments were repeated at least ﬁve times in triplicates with cells from
21 treated cells.
Fig. 2. b-Klotho expression in human adipocytes. (A) b-Klotho mRNA expression was determined in fractions from human adipose tissue (n = 14).
Expression was lower in the stroma-vascular (SV) portion compared to that of the adipocyte fraction. (B) b-Klotho expression was assessed in human
preadipocytes at the indicated time-points following induction of diﬀerentiation. Cells are fully diﬀerentiated at day 12. Values at day 8 and 12 were
signiﬁcantly higher than in samples from day 4. *P < 0.05 by Students paired t-test.
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duced during in vitro adipocyte diﬀerentiation (Fig. 2B).
3.3. Human FGF21 does not induce lipolysis in 3T3-L1 cells
Recent data have suggested that murine FGF21
(at 0.5 nmol/l) promotes lipolysis in 3T3-L1 adipocytes after
3–9 h of stimulation [5]. However, in our hands neither murine
nor human FGF21 induces an increase in glycerol release fromFig. 3. 3T3-L1 respond to FGF21 but display no eﬀect on lipolysis. (A) Expe
FGF21 up to 9 h. Human FGF21 was used at the same concentration as a com
(B) In order to assess whether the cells expressed the necessary signalling com
or murine FGF21 as described in Section 2. A signiﬁcant and robust increas
cells were incubated for 72 h with either medium or 150 nmol/l murine or hu
performed as described in Fig. 1A. *P < 0.05 and **P < 0.01 compared to
statistically signiﬁcant.3T3-L1 adipocytes (Fig. 3A) even though the conditions in
which we performed these experiments were identical to those
previously described [5]. We also performed dose–response
experiments with FGF21 using the same conditions but ob-
served no eﬀect on glycerol release at any concentration (data
not shown). The absence of FGF21 eﬀect on lipolysis in 3T3-
L1 adipocytes in our studies was not due to cell unresponsive-
ness to the protein as 3T3-L1 cells in parallel experiment wereriments were performed exactly as described [5] using 0.5 nM of murine
parison. There was no apparent increase of glycerol at any time-point.
ponents to respond to FGF21, cells were incubated with 0.5 nM human
e in ERK1/2 phosphorylation was observed. (C) Diﬀerentiated 3T3-L1
man FGF21 as indicated. After incubation, lipolysis experiments were
cells treated in medium only, by Students paired t-test. NS = not
1728 P. Arner et al. / FEBS Letters 582 (2008) 1725–1730activated by both murine and human FGF21 as evidenced in
an ERK1/2 phosphorylation assay (Fig. 3B). In order to assess
whether a more prolonged treatment with FGF21 could still
inﬂuence lipolysis, we performed experiments equivalent to
those described in Fig. 1A in diﬀerentiated 3T3-L1 cells.
Again, a 72 h-incubation of 3T3-L1 adipocytes with
150 nmol/l human or murine FGF21 had no eﬀect on basal
lipolysis but attenuated NA-stimulated lipid breakdown (Fig.
3C), similar to what we observed in human fat cells (Fig. 1A).
3.4. FGF21 does not decrease adipocyte diﬀerentiation
The attenuation of lipolysis in human adipocytes following
FGF21 treatment could arguably be secondary to an attenuat-
ing eﬀect of FGF21 on diﬀerentiation. To assess this we used
human MSCs diﬀerentiated according to standards procedures
in the presence or absence of diﬀerent concentrations of
FGF21. We observed a small but signiﬁcant concentration-
dependent eﬀect of FGF21 in increasing triglyceride content,
an indirect measure of adipogenic diﬀerentiation (Fig. 4A).
These experiments were repeated with diﬀerent adipogenic
media containing dexamethasone with or without insulin,
IBMX and rosiglitazone. However, the positive eﬀect of
FGF21 on lipid accumulation was similar in all experimental
conditions (graphs not shown). In addition, the activity of
the diﬀerentiation marker glycerol-3 phosphate dehydrogenaseFig. 4. FGF21 eﬀects on triglyceride content, mRNA and protein expressio
without FGF21 for 10 days. Adipocyte diﬀerentiation was quantitated as
comparisons were made by ANOVA followed by Dunnets multiple compari
for 3 days. Quantitative RT-PCR was performed and expressed relative to th
No signiﬁcant eﬀect of FGF21 was observed on the indicated genes in seven
in the presence or absence of FGF21 as indicated. Protein lysates were anal
below. PLIN protein expression was reduced by approximately 50% by FGF
Cells were also stimulated with NA or forskolin. This resulted in the pho
Although FGF21 reduced the protein levels of PLIN, there was no eﬀect o
inﬂuence PLIN phosphorylation (right panel). The experiments were repea
signiﬁcant; *P < 0.05 by Students paired t-test.(GPDH) was similar in adipocytes treated with or without
FGF21 (values not shown).
3.5. FGF21 treatment does not aﬀect gene expression of lipolytic
genes
In order to determine a possible mode of action in human
adipocytes, we investigated the eﬀect of FGF21 on the mRNA
levels of a set of genes known to regulate stimulated lipolysis.
A 72 h-incubation with FGF21 did not aﬀect the expression of
HSL, adipose-derived triglyceride lipase (ATGL), PLIN, pro-
tein kinase A regulatory protein 1a (PKA R1a), phosphodies-
terase 3B (PDE3B) or the adipogenic transcription factor
peroxisome proliferators-activated receptor gamma (PPARc)
(Fig. 4B).
3.6. FGF21 reduces PLIN protein levels in human adipocytes – a
possible mode of action
Since we observed no eﬀect of FGF21 on the expression of
common lipolytic genes we investigated its actions on protein
expression. FGF21 treated cells exhibited 50% lower PLIN lev-
els than control cells (Fig. 4C, left panel). To elucidate whether
FGF21 aﬀects PLIN phosphorylation, cells were stimulated
with NA or forskolin (Fig. 4C, right panel). Under these con-
ditions, a 72-h pre-treatment with FGF21 did not aﬀect PLIN
phosphorylation as determined by its migration in SDS–n in human adipocytes. (A) Human MSCs were diﬀerentiated with or
total lipid content and expressed relative to control cells. Statistical
son test. (B) Diﬀerentiated adipocytes were treated or not with FGF21
at of control (non-FGF21 stimulated) cells. 18S was used as reference.
independent experiments. (C) Diﬀerentiated adipocytes were incubated
yzed for total PLIN levels by Western blot and quantiﬁed as detailed
21 treatment in basal conditions (non-hormone-stimulated) (left panel).
sphorylation and hence an approximately 2 kDa shift in migration.
n the migration of PLIN in the gel, suggesting that FGF21 does not
ted four times with cells from diﬀerent donors. NS = not statistically
P. Arner et al. / FEBS Letters 582 (2008) 1725–1730 1729PAGE. FGF21 treatment had no eﬀect on HSL (Fig. 4C) or
ATGL protein expression (not shown).4. Discussion
We show here that human FGF21 has no acute but long-
term eﬀects on lipolysis in human fat cells, and these cells ex-
press b-klotho which is a prerequisite for FGF21 responsive-
ness [6]. A 3-day FGF21 treatment lowers catecholamine-
and ANP-stimulated lipolysis by 50%. The anti-lipolytic eﬀect
of FGF21 is at the post-receptor level since FGF21 attenuates
the eﬀect of forskolin as well as cyclic AMP analogues (data
not shown). FGF21 does not aﬀect expression of genes regulat-
ing lipolysis but may mediate its eﬀect by reducing PLIN pro-
tein expression due to post-transcriptional regulation. Since
attenuated lipolysis results in reduced NEFA release it is con-
ceivable that the anti-diabetic eﬀect of FGF21, at least in part,
may involve regulation of lipolysis. This is in line with animal
data showing that treatment with FGF21 results in reduced
circulating triglyceride levels [2,3]. Furthermore, since
FGF21 attenuates both NA and ANP-induced lipolysis its ma-
jor site of action should be lipolysis signalling steps where NA
and ANP converge, i.e at the level of HSL or below.
Recently, FGF21 has been shown to induce basal but not cat-
echolamine-stimulated lipolysis in murine 3T3-L1 adipocytes
[5]. However, using the conditions matching those described
in [5], we were not able to conﬁrm an increase in glycerol release
with either murine or human FGF21 using the same concentra-
tions and time-points. The 3T3-L1 cells used in this study were
responsive to FGF21 since both forms of the factor induced a
signiﬁcant increase in ERK1/2 phosphorylation, an indicator
of FGF21 activity on 3T3-L1 adipocytes [5]. Furthermore, no
eﬀect on basal lipolysis in 3T3-L1 cells was observed at a variety
of other concentrations of FGF21 (data not shown). When
repeating in 3T3-L1 cells the 72 h-incubations performed in hu-
man adipocytes, we observed no signiﬁcant eﬀect on basal lipol-
ysis using either murine or human FGF21. In contrast, and
similar to the ﬁndings in human adipocytes, hormone-stimu-
lated lipolysis was signiﬁcantly attenuated by FGF21 treat-
ment. Our data therefore clearly suggest that FGF21
attenuates stimulated, but does not aﬀect basal lipolysis in both
murine and human adipocytes.
The reason for the discrepancies between the present data and
the former work are not clear at the moment. Possibly, it can be
explained by the subtle diﬀerences in handling/diﬀerentiation of
3T3-L1 cells in diﬀerent laboratories that may inﬂuence the spe-
ciﬁcs of FGF21 functional response. Curiously, the circulating
levels of NEFAs were increased both when FGF21 was over ex-
pressed [5] or knocked down (following a ketogenic diet) [11].
The latter indeed is suggesting that in vivo FGF21 attenuates
lipolysis rather than promotes it. Thus, the reason for elevated
NEFAs in animals with both high and low FGF21 expression
remains to be deﬁned but it cannot be reconciled if FGF21
would only act by activating lipolysis. Increased expression of
HSL and ATGL in white adipose tissue of FGF21 transgenic
mice but not in 3T3-L1 cells suggests that the changes observed
in vivo may reﬂect an adaptive rather than a direct eﬀect [5].
There were no data presented on gene and protein expression
of PLIN in the studies using animal models [5,11].
The eﬀect of FGF21 on attenuating lipolysis is not second-
ary to de-diﬀerentiating eﬀect. This conclusion is based on sev-eral ﬁndings. First, we observed no FGF21-induced reduction
in PPARc mRNA expression (Fig. 4B), a crucial transcription
factor for adipogenesis. Second, there was no eﬀect on GPDH
activity, a well-established marker of adipogenic diﬀerentiation
(data not shown). Third, in adipocytes derived from hMSC,
FGF21 resulted in a signiﬁcant increase in lipid content, an
indirect measure of diﬀerentiation (Fig. 4A). Our present re-
sults are in line with recent data demonstrating a similar eﬀect
of FGF21 in 3T3-L1 cells [12]. In that work, FGF21 increased
triglyceride formation up to at least 240 nM, an eﬀect that was
potentiated by PPARc. Furthermore, recent publications sug-
gest that FGF21 is a PPAR downstream target [13]. Taken to-
gether, these data indicate that FGF21 may in fact promote
adipogenesis.
PLIN coats the intracellular lipid droplet and is phosphory-
lated upon lipolytic stimulation. Although the speciﬁc details
of this process are not entirely understood, PLIN is considered
to recruit HSL and other regulatory proteins to the lipid drop-
let surface for subsequent TG hydrolysis [14–17]. Our present
results are in line with data from PLIN / mice which dis-
play an almost abrogated response to catecholamine stimula-
tion [18,19]. However, PLIN knockout animals also display
an increased basal lipolysis. This is thought to be secondary
to a loss of a certain barrier function of PLIN [20]. In this
model, HSL and possibly other lipolytic enzymes such as
ATGL would have easier access to the lipid droplet surface
in the complete absence of PLIN. We observed no eﬀect of
FGF21 on basal lipolysis. This is most probably due to the fact
that FGF21 does not completely abolish PLIN expression in
adipocytes but only reduces it to a certain extent. The fact that
HSL protein levels were unaltered and that HSL migrated
identically irrespective of FGF21 treatment suggests that
HSL protein expression is not inﬂuenced by FGF21 and that
no major post-translational modiﬁcation (e.g. reduced phos-
phorylation) occurs following FGF21 treatment. Further stud-
ies on the intracellular compartmentalization of PLIN, HSL
and possibly ATGL upon FGF21 stimulation would neverthe-
less be of interest.
In conclusion, our results show that FGF21 attenuates hor-
mone-stimulated lipolysis in both human and murine adipo-
cytes. In vivo this would trigger a reduction of NEFA release
and could thereby contribute to the insulin sensitizing eﬀect
of FGF21. The decrease in lipolysis could also contribute to
a reduced lipotoxicity on islet cells in addition to the direct ef-
fects of FGF21 recently shown in beta cells. Our data also sug-
gest that a possible anti-lipolytic mechanism of FGF21 action
may be related to a post-transcriptional reduction of PLIN
expression, although at present we cannot exclude other poten-
tial eﬀects. Therefore, further studies are needed to deﬁne the
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